BACKGROUND: Attention deficit-hyperactivity disorder (ADHD) is a common disorder that has been associated with criminal behavior in some studies. Pharmacologic treatment is available for ADHD and may reduce the risk of criminality. METHODS: Using Swedish national registers, we gathered information on 25,656 patients with a diagnosis of ADHD, their pharmacologic treatment, and subsequent criminal convictions in Sweden from 2006 through 2009. We used stratified Cox regression analyses to compare the rate of criminality while the patients were receiving ADHD medication, as compared with the rate for the same patients while not receiving medication. RESULTS: As compared with nonmedication periods, among patients receiving ADHD medication, there was a significant reduction of 32% in the criminality rate for men (adjusted hazard ratio, 0.68; 95% confidence interval [CI], 0.63 to 0.73) and 41% for women (hazard ratio, 0.59; 95% CI, 0.50 to 0.70). The rate reduction remained between 17% and 46% in sensitivity analyses among men, with factors that included different types of drugs (e.g., stimulant vs. nonstimulant) and outcomes (e.g., type of crime). CONCLUSIONS: Among patients with ADHD, rates of criminality were lower during periods when they were receiving ADHD medication. These findings raise the possibility that the use of medication reduces the risk of criminality among patients with ADHD. (Funded by the Swedish Research Council and others.).
BACKGROUND:Attention deficit-hyperactivity disorder (ADHD) is a common disorder that has been associated with criminal behavior in some studies. Pharmacologic treatment is available for ADHD and may reduce the risk of criminality. METHODS: Using Swedish national registers, we gathered information on 25,656 patients with a diagnosis of ADHD, their pharmacologic treatment, and subsequent criminal convictions in Sweden from 2006 through 2009. We used stratified Cox regression analyses to compare the rate of criminality while the patients were receiving ADHD medication, as compared with the rate for the same patients while not receiving medication. RESULTS: As compared with nonmedication periods, among patients receiving ADHD medication, there was a significant reduction of 32% in the criminality rate for men (adjusted hazard ratio, 0.68; 95% confidence interval [CI], 0.63 to 0.73) and 41% for women (hazard ratio, 0.59; 95% CI, 0.50 to 0.70). The rate reduction remained between 17% and 46% in sensitivity analyses among men, with factors that included different types of drugs (e.g., stimulant vs. nonstimulant) and outcomes (e.g., type of crime). CONCLUSIONS: Among patients with ADHD, rates of criminality were lower during periods when they were receiving ADHD medication. These findings raise the possibility that the use of medication reduces the risk of criminality among patients with ADHD. (Funded by the Swedish Research Council and others.).
Authors: Björn Wettermark; Niklas Hammar; Carl Michael Fored; C MichaelFored; Andrejs Leimanis; Petra Otterblad Olausson; Ulf Bergman; Ingemar Persson; Anders Sundström; Barbro Westerholm; Måns Rosén Journal: Pharmacoepidemiol Drug Saf Date: 2007-07 Impact factor: 2.890
Authors: Lenard A Adler; Brenda Zimmerman; H Lynn Starr; Steve Silber; Joseph Palumbo; Camille Orman; Thomas Spencer Journal: J Clin Psychopharmacol Date: 2009-06 Impact factor: 3.153
Authors: Peter S Jensen; L Eugene Arnold; James M Swanson; Benedetto Vitiello; Howard B Abikoff; Laurence L Greenhill; Lily Hechtman; Stephen P Hinshaw; William E Pelham; Karen C Wells; C Keith Conners; Glen R Elliott; Jeffery N Epstein; Betsy Hoza; John S March; Brooke S G Molina; Jeffrey H Newcorn; Joanne B Severe; Timothy Wigal; Robert D Gibbons; Kwan Hur Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-08 Impact factor: 8.829
Authors: Suzanne McCarthy; Philip Asherson; David Coghill; Chris Hollis; Macey Murray; Laura Potts; Kapil Sayal; Ruwan de Soysa; Eric Taylor; Tim Williams; Ian C K Wong Journal: Br J Psychiatry Date: 2009-03 Impact factor: 9.319
Authors: Jessica C Agnew-Blais; Guilherme V Polanczyk; Andrea Danese; Jasmin Wertz; Terrie E Moffitt; Louise Arseneault Journal: Br J Psychiatry Date: 2018-06-29 Impact factor: 9.319
Authors: Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson Journal: Biol Psychiatry Date: 2019-04-17 Impact factor: 13.382
Authors: Alexander Viktorin; Eleonore Rydén; Michael E Thase; Zheng Chang; Cecilia Lundholm; Brian M D'Onofrio; Catarina Almqvist; Patrik K E Magnusson; Paul Lichtenstein; Henrik Larsson; Mikael Landén Journal: Am J Psychiatry Date: 2016-10-03 Impact factor: 18.112